Biosenic SA

BioSenic and Pluristyx sign term sheet for market availability of ALLOB mesenchymal cells

23 May 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic provides First Quarter 2023 Business Update

21 May 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic reacquires global IP rights and provides update on JTA-004 development

16 May 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic to host Annual General Meeting on June 14 2023

14 May 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic identifies key biomarkers for cGvHD and submits patent to EPO

03 May 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic announces 2022 full year results

26 Apr 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases

17 Apr 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic appoints Lieven Huysse, MD, as Chief Medical Officer

02 Apr 2023 22:30:00 By Nasdaq GlobeNewswire

BioSenic provides Financial Update and Financial Calendar 2023

30 Mar 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)

29 Mar 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population

15 Mar 2023 23:00:00 By Nasdaq GlobeNewswire

BioSenic SA: Information on the total number of voting rights and shares

01 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

BioSenic optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment

22 Feb 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic receives EUR 1 million from Pregene in accordance with terminated license agreement and expect new negotiations on common revisited grounds

20 Feb 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont

14 Feb 2023 08:45:00 By Nasdaq GlobeNewswire

BioSenic announces the approval and publication of the Prospectus for listing and admission to trading of the shares and subscription rights issued in the context of the capital increase by way of in kind contributions of Medsenic

07 Feb 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic SA : Information on the total number of voting rights and shares

31 Jan 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic appoints Yves Sagot as Independent Director

26 Jan 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic appoints Dr Carole Nicco as Chief Scientific Officer

17 Jan 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic SA : Information on the total number of voting rights and shares

04 Jan 2023 22:00:00 By Nasdaq GlobeNewswire